

Assessing the Impact of Thyroid Hormone Imbalance on Cardiovascular Health in Aging Populations

¹Ali Raza, ²Dr. Muhammad Idrees, ³Mohib Ali, ⁴Mobeen Ali, ⁵A Umar Khan

¹PIMS

²Senior Consultant Physician, DHQ Hospital, Narowal

³PIMS

⁴PIMS

⁵PIMS

Abstract

Aim: This review is aimed to elucidate the influence of thyroid hormone imbalance on cardiovascular health in aging populations highlighting its importance, aetiology, and risk factors with potential therapeutic strategies.

Methods: This review integrates the available evidence from a systematic search of the literature on epidemiological and clinical trials. This review is based on longitudinal and population surveys that provide data linking thyroid function tests to cardiovascular outcomes or in the form of controlled trials, case control studies which explored outcome following use of exogenous TH replacement therapy. The paper also examines possible physiological mechanisms such as those related to lipid profile, blood pressure control, cardiac function and their interactions with other cardiovascular risk factor in aging.

Discussion: The results indicate that THs exert a profound influence on the cardiovascular system, effects which provide explanations for their well-established association with heart rate regulation and normal cardiac rhythm (tachycardias) as well consequences of hyperthyroid disorders. Older adults are vulnerable to the impact of hypothyroidism and hyperthyroidism, imbalances in thyroid function that present specific cardiovascular risks from age-related changes on top gender differences resulting hormonal milieu. These involve screening based on guidelines, pharmacological therapies which include levothyroxine replacement therapy for hypothyroidism and non-pharmacologic interventions like changes to lifestyle behaviours aimed at improving cardiovascular risk.

Keywords: Thyroid Hormones, Cardiovascular Health, Aging Populations, Hypothyroidism.

Introduction

Thyroid hormones are largely responsible for keeping us healthy by controlling the essential functions of our body, such as metabolism and how it interacts with other hormonal systems during growth and development. It is from these basic functions that they represent a key signalling pathway in cardiovascular activity. The role of thyroid hormones in cardiovascular health is particularly relevant with advancing age, as changes in thyroid status associated with aging can impact the cardiovascular consequences of hypothyroidism and hyperthyroidism. Comprehending the implication of disrupted thyroid hormone towards cardiovascular health is essential for better management in elderly. It is relevant to clinical practice and as a guide in public health strategies that seek to mitigate risk associated with thyroid disease among the ageing population [1].

Thyroid hormones, primarily thyroxine (T4) and triiodothyronine (T3), are necessary for cellular metabolism in the entire body. These hormones have direct myocardial and vascular effects on heart rate, contractility, and tone. Both hypo- and hyperthyroidism create an imbalance in thyroid hormone levels, which disturbs homeostatic mechanisms to cause cardiovascular problems. Hypothyroidism, when hormone production is lacking (i.e.: low), has lower heart rates and higher levels of cholesterol leading to increase cardiovascular risk due it impair in cardiac contractility. On the

other hand, hyperthyroidism makes your heart beats faster and causes arrhythmias or irregular beatings of your heartbeat which can be very dangerous if you have a history of any cardiovascular diseases.

The prevalence of thyroid disorders increases with age in aging populations, a phenomenon that reflects changes in the physiology and regulation of hormones. These changes encompass the disruption of thyroid hormone production, diminished responsiveness of target tissues to T₃ and increased prevalence autoimmune thyroid diseases such as Hashimoto's. These results highlight the complex interplay and clinical importance of comprehensive assessment and management of thyroid health among older individuals. In light of the impact that thyroid hormones have on cardiovascular function, examining their potential contribution to age-related changes in CVD is critical [2].

It is alluded here in the thesis statement that it necessary to know and understand not only thyroid hormone imbalances as such affects cardiovascular health but more so in aging populations. This concept is fundamental as a starting point to design appropriate prevention and intervention strategies that would prevent heart failure in elderly subjects with thyroid dysfunction. This review aims to shed light on the complex interplay between thyroid function and cardiovascular health in an effort to unveil mechanisms, risk factors, as well as evidence-based management strategies so that CV sequelae can be mitigated among elderly populations.

Thyroid Hormones and the Cardiovascular System

Cardiovascular effects of the thyroid hormone's thyroid : influence on most aspects with respect to heart structure and function as well as vascular hemodynamic. A knowledge of this function is required for the understanding of many aspects related to heart, with particular regard to thyroid involvement in cardiovascular homeostasis.

Role of Thyroid Hormones in Regulation of Cardiovascular Functional.

Thyroid hormones (mainly thyroxine(T₄) and triiodothyronine(t₃)) have a critical role in cardiovascular function by multiple mechanisms as follows:

Thyroid hormone impact directly on cardiac myocytes, making heart more resistant to catecholamines and leading an increased sensibility of the heartrate increase also with a positive inotropism. T₃, the active form of thyroid hormone binds to nuclear receptors in cardiac cells and increases expression of genes involved in processes necessary for normal heart function such as contractility. This response is vital for achieving the cardiac output necessary to meet metabolic requirements [3].

Effects on Vascular Tone and Endothelial Function: Thyroid hormones also have an effect on vascular smooth muscle cells, endothelial cells that can alter the influence of both things by increasing or decreasing their reactivity as a consequence. T₃ is vasodilatory, an effect mediated in part via enhanced nitric oxide production and by effects on vascular smooth muscle responsiveness to vasoconstrictors. Also, thyroid hormones seem to be important for endothelial homeostasis by regulating the expression of endothelial nitric oxide synthase (Enos). E Dysfunction in those pathways may lead to arterial stiffness and hypertension associated with thyroid disorders.

Classification of Thyroid Disorders Causing Cardiovascular Morbidity

The alterations in heart rate, contractility and vascular function plays a key role for the cardiovascular health but also for thyroid disorders as hypothyroidism or hyperthyroidism.

Under-active thyroid: The under-production of the thyroid hormones from an unhealthy activity by the gland itself. This condition is characterised by not only reduced metabolic rate, but also decreased cardiac output resulting in bradycardia (low heart rate), and diminished myocardial contractility. These will manifest as fatigue, cold intolerance and total body fluid dilatation. In addition, hypothyroidism is accompanied by lipid disorders manifested in an increase of concentration cholesterol and triglycerides which can facilitate the progress atherosclerosis changes over time Additionally, deficient endothelial function and reduced nitric oxide bioavailability contributing towards the development of hypertension and vascular dysfunction in hypothyroid has been well documented .

Hyperthyroidism: This type is defined by an excess of thyroid hormones production. This condition is known by hypermetabolic state and increase in sympathetic activity which cause tachycardia (increased HR), palpitations, with the increased cardiac contractility. Hyperdynamic circulation from hyperthyroidism clearly predisposes to atrial fibrillation and other arrhythmias. Also, hyperthyroidism alters lipid metabolism and decrease the levels of total cholesterol, along with LDL cholesterol while paradoxically increasing HDL explaining all together a desirable lipoprotein pattern. These lipid perturbations, as well as increased oxidative stress and inflammation enhances endothelial dysfunction promoting accelerated atherosclerosis despite the outcome improvement appearance of lipids profile.

Cardiovascular manifestations are common in both hypothyroidism and hyperthyroidism, necessitating meticulous evaluation and management to prevent complications and enhance cardiovascular outcomes. In hypothyroidism, thyroid hormone replacement therapy is necessary to correct the levels of those hormones and restore some (but not all) cardiovascular abnormalities. On the other hand, hyperthyroidism treatment includes antithyroid drugs, radioactive iodine and surgery aiming to correct thyroid hormone levels restoring cardiovascular symptoms [4]. In conclusion, thyroid hormones influence cardiovascular function through regulation of heart rate, contractility, vascular tone and endothelial biology. This process is vital to the control of metabolism and prolonged or repetitive dysfunction-whether it be hypothyroidism (low thyroid hormone level) or hyperthyroidism (elevated thyroid hormone)-has far-reaching implications for cardiovascular health, culminating in a plethora of cardiovascular disorders including dyslipidaemia, hypertension and arrhythmias. Knowledge of these pathogenic mechanisms are central to the proper management of thyroid disorders and cardiovascular health in those with its diagnosis.

Methods of Assessing Impact

View Full-Text Assessment of the Effects of Thyroid Hormone Imbalance on Cardiovascular Health-A Comprehensive

Overview Using Clinical Information from Epidemiological and Longitudinal Survey-based Studies.

Epidemiological Studies

Epidemiological studies are invaluable in investigating the temporal trends of and population-based risks for cardiovascular outcomes associated with thyroid function using large databases, such as:

Longitudinal Studies Relating Thyroid Function Tests to Cardiovascular Outcomes:

Longitudinal, participants are followed for multiple periods and thyroid function is assessed by measuring the biomarkers such as TSH (thyroid stimulating hormone), FT4 (free thyroxine) or T3 triiodothyronine. Studies accounting with cardiovascular events. Studies were seeking to determine the impact of variations in thyroid hormone levels over time on risk for cardiovascular diseases (CVD), i.e., myocardial infarction, stroke and/or heart failure. These studies provide evidence that TSH and FT4 are predictive of an increased risk for cardiovascular disease (CVD), particularly in individuals with subclinical thyroid dysfunction.

Population-based surveys estimating the prevalence of thyroid disorders in defined populations and their risk to cardiovascular disease. These studies investigate the prevalence of hypothyroidism, hyperthyroidism and autoimmune thyroid diseases (Hashimoto's thyroiditis or Graves' disease) using population-based samples. These surveys offer insights into tailored public health strategies for cardiological risk stratification across thyroid disorder categories to care the ensuing cardiovascular complications from diagnosis or even in preventive circumstances [5].

Clinical Studies

Thereby, clinical studies represent ideal controlled scenarios for evaluating the efficacy of interventions and are better able to determine a valid cause-and-effect relationship between thyroid diseases and cardiovascular outcomes: Clinical trials comparing thyroid hormone replacement therapies: Clinical studies assess the beneficial and deleterious effects of various forms of thyroid hormone replacement (e.g., levothyroxine for hypothyroidism) on indices of cardiovascular function, as well as patient

outcome. Randomized controlled trials with placebo or active control groups assess treatment efficacy to improve heart function (including cardiac and metabolic effects, such as positive chronotropic changes), lipid coverings and vascular health following hormonal therapy. The outcomes from these studies are critical in determining the appropriate therapy and for developing recommended treatment algorithms based on (iatrogenic) profile-specific endpoints as well as cardiovascular adverse outcomes directly linked to thyroid hormone deprivation.

Case-Control Studies of Cardiovascular Events in Thyroid Disorder Patients: Case-control studies compare the occurrence retrospectively (e.g. myocardial infarction, atrial fibrillation) among patients with diagnosed thyroid disorders versus age-matched individuals having euthyroidism. These are case-controlled studies in which the potential confounding factors such as age, sex and co-morbidities have been accounted for when estimating cardiovascular morbidity or mortality from thyroid dysfunction. Case-control studies provide clinical insights by delineating particular cardiovascular risks posed in hypothyroidism or hyperthyroidism, thereby shedding light over age-appropriate surveillance and risk stratification that should be considered along with pre-emptive interventions towards an improved management of thyroid disorders.

Overall, epidemiological as well clinical studies are indispensable methodologies to evaluate the influence of modulations in thyroid hormone status on cardiovascular health. Population-level trends in thyroid disorder prevalence and associated cardiovascular risks are elucidated by epidemiological approaches, which may inform public health initiatives and preventive strategies. To date, clinical evidence from longitudinal cohorts and controlled trials has offered mechanisms underlying the causal relationships between thyroid dysfunction and cardiovascular outcomes in guiding of management decades after therapeutic interventions. Integrated altogether, these methodologies provide a much-needed whole-person insight into the collective impact of thyroid hormone signalling on cardiovascular health and will ultimately enable personalized

ways to reduce CVD risks in states of altered thyro-metabolic state [6].

Physiological Mechanisms

Disruption of thyroid hormone function affects multiple physiological processes that are important to cardiovascular health. This knowledge will allow a greater insight into pathophysiological pathways present in the relationship between thyroid dysfunctions and development of cardiovascular diseases, mostly experienced by an aging population group.

FUNCTIONAL IMPAIRMENT BY THYROID HORMONE IMBALANCE

Atherosclerosis & Lipid Profile: Thyroid hormones have a profound effect upon lipid metabolism, modulating cholesterol synthesis (30), clearance and mobilization of triglycerides. Decreased thyroid hormone levels in hypothyroidism slow lipolysis and clearance of circulating lipoproteins, producing increases in total cholesterol LDL-cholesterol, and triglycerides; These lipid abnormalities are implicated in the pathogenesis of atherosclerosis, which is characterized by the accumulation of cholesterol-rich plaques within arterial walls. In contrast, there is a higher lipid metabolism in hyperthyroidism with lower total cholesterol and LDL-cholesterol levels accompanied by increased HDL-cholesterol. Hyperthyroidism has some favourable effects on lipid profile; however, it is associated with hyper reactive oxidative stress and endothelial dysfunction leading to atheromatous plaque formation and progression. These results that hypo- and hyperthyroidism, by divergent regulation of lipid metabolism saturates the lipid transport systems leading to increased benefit from the LDL receptor-mediated uptake in atherosclerosis.

Thyroid hormones influence blood pressure regulation directly by inducing changes in systemic vascular resistance and heart rate, as well as indirectly through their effects on cardiac output and renal function. Hypothyroidism is a known cause of systemic hypertension, secondary to increased peripheral vascular resistance and reduced renal blood flow concomitantly mediated by alterations in vascular tone as well as endothelial function. On the other hand, hyperthyroidism is its polar opposite: this presentation includes a super-hyperdynamic circulation (high output and low

systemic vascular resistance), which results in systolic hypertension with wide pulse pressures. In patients with untreated thyrotoxicosis, these hemodynamic changes result in an increased rate of atrial fibrillation and myocardial ischemia as well as more heart failure than in euthyroid individuals. Restoration of blood pressure homeostasis and reduction in cardiovascular risk depend on proper management of thyroid hormone levels in these patients [7].

Cardiac function and arrhythmias: thyroid hormones are essential for normal cardiac contractility, electrical conduction, and rhythm. Atrial and ventricular arrhythmias in these patients are predisposed by bradycardia, reduced myocardial contractility which occur in conjunction with prolonged QT intervals related to decreased thyroid hormone levels typical of hypothyroidism. Moreover, hypothyroid heart showed diastolic dysfunction and myocardial stiffness increased in addition to induced HFPEF. On the other hand, hyperthyroidism increases heart rate, improves myocardial contractility and reduces QT interval leading to a greater prevalence of supraventricular arrhythmias including atrial fibrillation (AF) or flutter. Such arrhythmias predispose to cerebrovascular and heart failure which necessitates ongoing monitoring of the heart rhythm in hyperthyroid patients, considering cardiovascular complications.

Interaction with Other Cardiovascular Risk Factors for Aging

Thyroid hormone imbalance influences these factors and, in this way, can exacerbate the cardiovascular profile of aging populations:

Potential impact on insulin resistance and metabolic syndrome: Thyroid hormones act to influence whole body glucose metabolism and insulin sensitivity, where hypothyroidism is a well-known cause of state of chronic low-grade inflammation that may result in insulin resistant conditions such as Metabolic Syndrome. Decreased levels of thyroid hormone affect glucose utilization and insulin signalling pathways which increase hyperglycaemia, dyslipidaemia as well as central obesity. These metabolic abnormalities are associated with higher incidence of type 2 diabetes mellitus and atherosclerotic cardiovascular diseases in hypothyroid subjects. Hyperthyroidism, on the

other hand, leads to increased production of glucose and improved insulin sensitivity with an accelerated metabolism so it may hide underlying insulin resistance initially. However, long-term hyperthyroidism promotes skeletal muscle catabolism and weakness as well as cachexia [9], enhancing the susceptibility of patients to cardiovascular comorbidities.

Effects on Inflammation and Oxidative Stress: Via their effects in cellular metabolism and gene expression, thyroid hormones have a significant impact upon immune function, inflammation-modulation, as well as fabricating up of free radicals. Hypothyroidism has been associated with systemic inflammation and high serum levels of pro-inflammatory cytokines and oxidative stress markers. In hypothyroid patients, chronic inflammation leads to endothelial dysfunction, vascular remodelling and plaque instability which may cause accelerated atherosclerosis with cardiovascular events. On the other hands, hyperthyroidism increased Oxidative stress and reactive oxygen species (ROS) production that result in lipid peroxidation, DNA damage and mitochondria dysfunction. These oxidative stress mechanisms may account for endothelial dysfunction, myocardial injury and arrhythmogenesis in the context of untreated hyperthyroidism [8].

The interplay with other major cardiovascular risk factors likely exacerbates the overall burden in aging populations moreover. Effective strategies for the prevention of cardiovascular complications, due to thyroid disorders, encompass management on many levels such as that affecting: 1) thyroid functioning; 2) lipid metabolism; 3) blood pressure regulation by pharmacological means; and/or non-pharmaceutical interventions potentially addressing glucose metabolism improvement in the fasting state with weight loss or using pharmaceutical agents separately without promoting hypoglycaemia (Second Dapagliflozin Cardiovascular Outcomes Event efficacy Trial [DECLARE-TIMI-58], which studied dapagliflozin); additionally serum potassium level lowering drugs in refractory cases recalcitrant to prior optimisation but with Evercare through Hammersmith experience leading...mPid_SEP_pledge body protection

plan(INVOKE-INPACT trial), targeting inflammation cardiologic issues has also been key, along side anti-inflammatory therapy reversing plasmatic flow disruption trihedron development project towards this A comprehensive, multidisciplinary approach focused on modification of thyroid-specific and cardiovascular risk factors may contribute to optimizing heart health in elderly middle-aged individuals with late-life DTC-associated structural vascular alterations.

Impact on Aging Populations

Given the relationship of thyroidal function to aging populations and cardiovascular health, we hypothesize that thyroid disorders in these settings will exert a major effect on our understanding of adult human endocrine physiology. This understanding is key to managing thyroid-related comorbidities and for ensuring the best of health in this aging population.

Prevalence of Thyroid Disease in the Elderly
Age-Related Thyroid Function Changes :
Aging is accompanied by intricate changes in thyroid function, this provides novel insights of physiology alterations termed as "thyroid senescence". These changes include decreased synthesis and secretion of thyroid hormones, alterations in feedback mechanisms, an increased prevalence of thyroid nodules and autoimmune thyroid diseases. One of the most common thyroid disorders in older persons is subclinical hypothyroidism, where TSH levels are elevated and there have abnormality with thyrotropin-sensitive target tissues without outward clinical signs of hormone deficiency. On the other hand, a rarer condition in elderly populations is similar scenario with low TSH levels but normal thyroid hormone concentrations: subclinical hyperthyroidism. As there are inevitable age-associated changes in the function of our thyroid this can obviously lead to a broad range of clinical presentations that we all know about such as fatigue, weight and cognitive decline with patients presenting for closer follow up, watch and wait or management.

Sex and Gender Differences: Thyroid Disorders are more common in women than men, particularly among older people. The association between the prevalence of hypothyroidism and autoimmune thyroid

diseases, such as Hashimoto's thyroiditis, with advancing age is more consistent in elderly women than men due to hormonal influences and genetic predispositions. Sex steroids including estrogen, progesterone and others can influence the synthesis, secretion or metabolism of thyroid hormone by binding to receptors in these tissues which may alter normal physiology status that causes specific sex-related patterns entry menopause as well aging. Aging-related hormonal changes, as well as genetic predisposition and environmental factors likely play a role in the distinct epidemiology and clinical expression of thyroid disorders that distinguish between elderly men vs. women [9].

Elderly patients with thyroid disorders are at unique cardiovascular risks for several reasons: increased susceptibility to adverse events, challenges in diagnosis and management. In hypothyroidism, elderly age acts as an important risk factor due to increased predisposition to atherosclerosis, myocardial infarction, and heart failure due to the presence of other risk factors, such as dyslipidaemia, hypertension, and insulin resistance. In the setting of hypothyroidism, a well-known pro-inflammatory and pro-thrombotic state contributes to cardiovascular morbidity and mortality even further. In hyperthyroidism, processes of predilection in the elderly such as progression to atrial fibrillation and heart failure with reduced ejection fraction are accelerated by conditions such as hyperthyroidism. It poses a significant risk of thromboembolic events and hemodynamic stress to affected people. In addition to increased risk of adverse events, the diagnosis and management of elderly patients is challenging due to poor sensitivity of thyroid function tests and overlapping symptoms of thyroid disorders with other elderly age conditions. Hormonal signalling and TSH production might be difficult due to blunted response of an aging pituitary to TRH. Moreover, patients with thyroid disorders are likely to suffer form serious comorbid conditions, such as cardiovascular disease, chronic kidney disease, and cognitive impairment. Therefore, patient and tailored treatment including thyroid hormone replacement therapy, antithyroid medications,

or radioactive iodine therapy should carefully weigh patient's risks and benefits in the context of age-related changes and multimorbidity patterns [10].

In conclusion, thyroid disorders play a relevant part in the aging populations by altering physiology of thyroid function, increasing cardiovascular risks and diagnostic/therapeutic difficulties. Specific considerations of the distinctive physiology and clinical aspects accompanying thyroid disorders in elderly people are, therefore, critical for achieving optimal health benefits supported by lower cardiovascular morbidity and improved quality-of-life status within an otherwise more fragile population. We should develop comprehensive strategies including goal-oriented care, multidisciplinary judgment and personalized approaches for the management of thyroid disorders to reduce cardiovascular complications in elderly.

Clinical Relevance and Treatment

Effective management of elderly patients with thyroid disorders encompasses the need for routine screening, strict monitoring and individualized approach to intervention in order to optimize their cardiovascular risk factors.

Screening and Monitoring treatment of Thyroid dysfunction in Elderly

Screening Guidelines: The recommended lower threshold of serum TSH level is 5 mIU/L (in our laboratory it had been previously reached) are DOI system, this recommends thyroid screening for all patients aged above 60. 2013 restatement inarticulacy presence in general population thyroid disease patients peaklet us to determine the predictive value of recurrent thyroidal ingestion retreatment niveous. The screening usually used to evaluate thyroid function is serum levels of TSH (thyroid-stimulating hormone). If the TSH level is high, then this leads you to have hypothyroidism and if it is low means hyperthyroidism. Elderly patients showing symptoms of wear associated with thyroid dysfunction, such as fatigue changes in body composition cognitive decline and vascular nice faction should decree screening.

MONITORING PROTOCOLS : After being diagnosed with a thyroid disorder elderly patients must be monitored regularly to check their thyroid function for treatment outcomes or

any changes of medications and complications. However, monitoring intervals might be more frequent in the case of severe thyroid dysfunction and a poor response to treatment. Otherwise, are monitored 6-12 monthly in patients who: Are stable on T4 for primary hypothyroidism (as following above) Have hyperthyroidism on treatment with antithyroid or TT PO radiation['___'NOTE to Me; _('Started translating but the end of it is not clearly visible') points. Remove At(points. Count - 1). Thyroid and aging populations: thyroxine replacement close monitoring to prevent from over or undertreat forgiveness with optimal hormone levels more the adverse cardiovascular consequences of thyroid diseases [11].

Pharmacological and Non-Pharmacological Interventions

Role of Thyroid hormone Replacement Therapy:

Hypothyroidism: Levothyroxine replacement therapy is the mainstay of treatment in elderly hypothyroidism patients. The treatment goal is to restore euthyroidism and relieve symptoms of thyroid hormone deficiency. Levothyroxine should be started at a low dose with progressive upscaling depending on the individual response and TSH regular monitoring. Because of the diminished metabolic rate and increased susceptibility to heart effects, elderly patients may be started on a lower dose. The regular monitoring of TSHs helps adjust the medication to keep the patient euthyroid and optimize cardiovascular outcomes. **Hyperthyroidism:** Pharmacologic therapy of hyperthyroidism in elderly patients' centres on decreasing the hormone production and treating the symptoms. Antithyroid drugs like methimazole or propylthiouracil are given initially to establish euthyroidism. Radioiodine may be considered in elderly patients as they are diagnosed to manage hyperthyroidism. By destroying the overactive thyroid tissue, radioiodine can normalize thyroid working in elderly patients. Extreme caution is required to manage overtreatment and treat any complications like agranulocytosis with antithyroid drugs and radiation thyroiditis after radioiodine therapy in the elderly. Other interventions Dietary modifications: Adequate balanced diets rich in vegetables, fruits, whole

grains, and lean proteins promote general health and may help manage weight fluctuations synonymous with thyroid disorders. Patients with hypothyroidism should also be educated on the recommended dietary iodine intake. Physical activity: Aging patients with thyroid disorders benefit from physical exercises due to the high metabolism and working hearts. Individual tailored exercises improve metabolic rates and promote weight management in addition to reducing the heart-working rate. Exercise contributes to mood stabilization and boosts the overall body function reducing the fatigue and depressed feelings associated with the diseases.

Counsel to Cease Smoking and Limit Alcohol: Elderly patients are encouraged to quit smoking completely; smoke cessation and limit alcohol consumption decreases Chad risks relevant with thyroid disorders. In patients with hypothyroidism, smoking cessation improved cardiovascular outcomes and the response to thyroid hormone replacement (THR) therapy. Reducing alcohol consumption prevents the risk of interactions with thyroid medications and supports healthy aging.

Conclusions: Management of thyroid diseases in older people should follow the screening guidelines and contain careful control of RR, aiming at reaching a targeted level that avoids both hyperthyroidism and hypothyroidism. Medications like thyroid hormone replacement therapy and antithyroid drugs are integral to maintaining euthyroidism and managing symptoms of hypo/hyperthyroidism. Lifestyle modifications and cardiovascular risk reduction strategies serve as non-pharmacological approaches enhancing medical therapy in those specific aging thyroid populations for a global health promotion. The optimal delivery of clinical care will require a combined management strategy to optimize outcomes, improve quality of life and reduce cardiovascular morbidity related with thyroid dysfunction in the elderly population.

Conclusion

In summary, the situation of thyroid hormone imbalance in aged people and cardiovascular health reproaches a complex interrelationship which should be treated with caution. Thyroid hormones are thought to be important modulators of cardiovascular function, altering

heart rate and vascular tone as well as lipids metabolism. Hyperthyroidism and hypothyroidism are associated with both common as well as specific cardiovascular risks, highlighting the need for accurate diagnosis which can be achieved by systematic testing of thyroid function. Functional and management strategies, including pharmacologic (thyroid hormone replacement therapy) and lifestyle interventions to reduce cardiovascular risk factors are essential for maintaining clinical wellbeing in older adults. Additional studies based on personalized medicine approaches and further insights into the mechanisms involved should help these tools to be more refined to improve quality of life in an aging population that presents with thyroid disorders.

References

- [1] H. Vargas-Uricoechea, "Effects of thyroid hormones on the heart Efectos de las hormonas tiroideas en el corazón," *Clínica e Investigación en Arteriosclerosis*, vol. 26, no. 6, pp. 296-309, 2014.
- [2] T. Ichiki, "Thyroid hormone and atherosclerosis," *Vascular Pharmacology*, vol. 52, no. 3-4, pp. 151-156, 2010.
- [3] A. A. Manolis, "Subclinical thyroid dysfunction and cardiovascular consequences: An alarming wake-up call?," *Trends in Cardiovascular Medicine*, vol. 30, no. 2, pp. 57-69, 2020.
- [4] M. L. B. Arcos, "Role of thyroid hormones-induced oxidative stress on cardiovascular physiology," *Biochimica et Biophysica Acta (BBA) - General Subjects*, vol. 1866, no. 12, p. 130239, 2022.
- [5] A. P. D.M.D, "Management of patients with thyroid disease: Oral health considerations," *The Journal of the American Dental Association*, vol. 133, no. 7, pp. 849-858, 2002.
- [6] G. B. Corssac, "Thyroid hormones effects on oxidative stress and cardiac remodeling in the right ventricle of

- infarcted rats," *Life Sciences*, vol. 146, no. 1, pp. 109-116, 2016.
- [7] M. J. Cheserek, "Cardioprotective effects of lipoic acid, quercetin and resveratrol on oxidative stress related to thyroid hormone alterations in long-term obesity," *The Journal of Nutritional Biochemistry*, vol. 33, pp. 36-44, 2016.
- [8] Z. Cai, "Imbalance of cardiac autonomic nervous activity and increase of ventricular repolarization dynamicity induced by thyroid hormones in hyperthyroidism," *Autonomic Neuroscience*, vol. 213, pp. 86-91, 2018.
- [9] R. Dittrich, "Thyroid hormone receptors and reproduction," *Journal of Reproductive Immunology*, vol. 90, no. 1, pp. 58-66, 2011.
- [10] A. L. d. Castro, "Cardioprotective effects of thyroid hormones in a rat model of myocardial infarction are associated with oxidative stress reduction," *Molecular and Cellular Endocrinology*, vol. 391, no. 1-2, pp. 22-29, 2015.
- [11] A. V. Skalny, "Serum trace elements are interrelated with hormonal imbalance in men with acute ischemic stroke," *Journal of Trace Elements in Medicine and Biology*, vol. 43, pp. 142-147, 2017.
- [12] I. v. Hoek, "Interactions between thyroid and kidney function in pathological conditions of these organ systems: A review," *General and Comparative Endocrinology*, vol. 160, no. 3, pp. 205-215, 2009.